Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000178725 | SCV000230866 | pathogenic | not provided | 2014-08-12 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001194307 | SCV001363734 | pathogenic | Fabry disease | 2019-03-13 | criteria provided, single submitter | clinical testing | Variant summary: GLA c.801+3A>G alters a conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Three predict the variant abolishes a 5' splicing donor site. Two predict the variant weakens a 5' donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing, reporting a 36-nucleotide insertion of intron sequence into the mRNA (Dobrovolny_2005). The variant was absent in 178758 control chromosomes. c.801+3A>G has been reported in the literature in individuals affected with Fabry Disease (Dobrovolny_2005, Shabbeer_2006). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar in 2014 without evidence for independent evaluation, and it was classified as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Genome- |
RCV001194307 | SCV002054403 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing |